<DOC>
	<DOCNO>NCT00526045</DOCNO>
	<brief_summary>This phase I/II , open-label , multicenter study AUY922 administer intravenously patient advance solid malignancy determine maximum tolerate dose . Phase II expansion arm investigate efficacy patient either HER2 positive ER positive locally advanced metastatic breast cancer . Additional patient advance solid malignancy also investigate separate expansion arm . Safety , pharmacokinetics pharmacodynamics assess .</brief_summary>
	<brief_title>Phase I-II Study Determine Maximum Tolerated Dose ( MTD ) AUY922 Advanced Solid Malignancies , Efficacy HER2+ ER+ Locally Advanced Metastatic Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>1 . Doseescalation MTD dose expansion arm : Patients histologically confirm , advance malignant solid tumor whose disease progress standard therapy standard therapy exist . Breast cancer phase II expansion arm : 1 . Females patient HER2 positive nonoperable locally advanced metastatic breast cancer must : History trastuzumab resistance , define either local systemic disease progression treatment least 8 week trastuzumab contain regimen . Received 3 prior anti HER2 base regimen ( i.e . trastuzumab and/or lapatinib combination agent ) metastatic disease Patients develop metastasis receive adjuvant neoadjuvant trastuzumab eligible . HER2 positive patient , tumor/s must demonstrate HER2 overexpression base either : Immunohistochemistry ( IHC ) 3+ level , IHC 2+ confirm fluorescence insitu hybridization ( FISH ) . Tumors test FISH must positive specific FISH assay amplification HER2 . 2 . Female patient ER positive nonoperable locally advanced metastatic breast cancer patient receive standard sequence line endocrine therapy whose disease progress least one 3 line endocrine and/or cytotoxic therapy advance disease . 2 . All patient must least one measurable lesion define RECIST . Irradiated lesion evaluable disease progression . 3 . All patient must progressive disease enter study 4 . Age ≥ 18 year . 5 . World Health Organization ( WHO ) Performance Status ≤ 2 . 6 . Life expectancy ≥ 12 week . 7 . Absolute Neutrophil Count ( ANC ) 1.5 x 109/L ; hemoglobin ( Hgb ) 9 g/dl ; platelet ( plt ) 100 x 109/L ; potassium , calcium , magnesium phosphorus within normal limit correctable supplement ; AST/SGOT ALT/SGPT ≤ 2.5 x Upper Limit Normal ( ULN ) ≤ 5.0 x ULN liver metastases present ; serum bilirubin 1.5 x ULN ; serum albumin &gt; 2.5g/dl serum creatinine 1.5 x ULN 24hour clearance 50 ml/min Exclusion criterion : 1 . Patients CNS metastasis : Symptomatic Require treatment symptom control and/or Growing Note : patient without clinical sign symptom CNS involvement require CT/MRI brain 2 . Prior treatment HSP90 HDAC inhibitor compound . 3 . Patient receive systemic anticancer treatment prior first dose AUY922 within follow time frame : Chemotherapy within 4 week Radiotherapy within 4 week Palliative radiotherapy : within 2 week Trastuzumab treatment within 4 week Nitrosoureas , mitomycin monoclonal antibody ( except trastuzumab ) : within 6 week Any continuousdosing ( i.e . daily dosing , everyotherday dosing , Monday WednesdayFriday dosing , weekly etc ) systemic anticancer treatment recovery period know , investigational drug ( i.e . targeted agent ) within duration ≤ 5 half life agent active metabolite ( ) 4 . Patients recover side effect previous systemic anticancer therapy less grade 2 CTCAE prior first dose . 5 . Pregnant lactating woman . 6 . Cardia exclusion criterion : History ( family history ) long QT syndrome . Mean QTc ≥ 450 msec screen ECG History clinically manifest ischemic heart disease include myocardial infarction , stable unstable angina , coronary arteriography cardiac stress testing/imaging finding consistent coronary occlusion infarction , ≤ 6 month prior study start . History heart failure leave ventricular ( LV ) dysfunction ( LVEF ≤ 45 % ) MUGA ECHO 7 . Known diagnosis HIV infection ( HIV test mandatory ) . 8 . Acute chronic liver disease , acute chronic renal disease concurrent severe and/or uncontrolled medical condition ( e.g . uncontrolled diabetes , active uncontrolled infection ) could cause unacceptable safety risk compromise compliance protocol . 9 . Cardiac exclusion criterion : Mean QTc ≥ 450 msec screen ECG clinically significant ECG abnormality include one following : left bundle branch block ( LBBB ) , right bundle branch block ( RBBB ) leave anterior hemiblock ( LAHB ) . ST segment elevation depression &gt; 1mm , 2nd ( Mobitz II ) 3rd degree AV block ; clinically significant ECG abnormality include one following : left bundle branch block ( LBBB ) , right bundle branch block ( RBBB ) leave anterior hemiblock ( LAHB ) . ST segment elevation depression &gt; 1mm , 2nd ( Mobitz II ) 3rd degree AV block . History ( family history ) long QT syndrome , heart failure leave ventricular ( LV ) dysfunction ( LVEF ≤ 45 % ) MUGA ECHO , history clinically manifest ischemic heart disease include myocardial infarction , stable unstable angina , coronary arteriography cardiac stress testing/imaging finding consistent coronary occlusion infarction , ≤ 6 month prior study start ; history presence atrial fibrillation , atrial flutter ventricular arrhythmia include ventricular tachycardia Torsades de Pointes . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>AUY922</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Phase I/II</keyword>
	<keyword>Advanced Solid malignancy ( Phase I )</keyword>
	<keyword>Breast Cancer ( Phase II )</keyword>
	<keyword>HER2+</keyword>
	<keyword>ER+</keyword>
	<keyword>HSP90</keyword>
</DOC>